DJIA 16,408.54 -16.31 -0.10%
NASDAQ 4,095.52 0.00 0.00%
S&P 500 1,864.85 2.54 0.14%
market minute promo

240.10 2.59 (1.09%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ICPT $240.10 1.09%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $235.70
Previous Close $237.51
Daily Range $227.50 - $251.00
52-Week Range $30.38 - $497.00
Market Cap $4.7B
P/E Ratio -63.86
Dividend (Yield) $0.00 (0.0%)
Volume 523,009
Average Daily Volume 718,960
Current FY EPS -$3.32

Sector

Industry

Intercept Pharmaceuticals, Inc. (ICPT) Description

Intercept Pharmaceuticals, Inc. Website: http://www.interceptpharma.com/

News & Commentary Rss Feed

Can You Still Ride This Month's 3 Biggest Winners To Greater Gains?

Biotech dominates in January as Intercept, Cell Therapeutics, and Neurocrine all surge after good drug-trial news.

Intercept Pharmaceuticals Inc (ICPT): Today's Featured Drugs Laggard

Positive Results on Intercept Pharma's OCA - Analyst Blog

Intercept Pharmaceuticals Larger Than S&P 500 Component PerkinElmer

Insider Trading Alert - PXLW, DORM And ICPT Traded By Insiders

Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc., Micron Technology Inc., Facebook Inc.

Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc., Micron Technology Inc., Facebook Inc.

Sector Update: Healthcares Flat to Lower Pre-Market; Lexicon Soars 20% on Study of Diabetes Treatmen

Sector Update: Healthcares Flat to Lower Pre-Market; Lexicon Soars 20% on Study of Diabetes Treatment

Sector Update: Healthcares

Intercept Pharmaceuticals (Part IIa) - Quick Takeaways On OCA From EASL Abstracts And Presentations

Intercept Issues Preclinical Data Showing OCA's Potential Role in Preventing Complications of Cirrho

Intercept Issues Preclinical Data Showing OCA's Potential Role in Preventing Complications of Cirrhosis

Intercept Pharmaceuticals (Part II): The Short Story Is Over, Time For The Long Story

See More ICPT News...